I agree that this site is using cookies. You can find further informations here.
X
Yu, Yongfeng
848  results:
OpenAccess-fulltext X
Search for persons X
?
1

Cisplatin-induced Pyroptosis Enhances the Efficacy of PD-L1..:

Xuzhang, Wendi ; Lu, Tingting ; Jin, Weiqiu...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758111/.  , 2024
Link: http://www.ncbi.nlm.nih...
 
?
2

Comprehensive molecular characterizations of stage I–III lu..:

Ye, Ronghao ; Yu, Yongfeng ; Zhao, Ruiying..
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932204/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
3

Treatment strategies based on different oligoprogressive pa..:

Xuzhang, Wendi ; Huang, Huayan ; Yu, Yongfeng...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989452/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
4

Gumarontinib in patients with non-small-cell lung cancer ha..:

Yu, Yongfeng ; Zhou, Jianya ; Li, Xingya...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121392/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
5

Chinese multidisciplinary expert consensus on the managemen..:

Zhang, Li ; Wang, Yongsheng ; Lin, Lizhu..
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10748904/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
6

Clinical definition of secondary resistance to immunotherap..:

Huang, Dingzhi ; Lin, Gen ; Chu, Qian...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693946/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
7

Immunotherapy strategies for EGFR-mutated advanced NSCLC af..:

Li, Xingyuan ; Huang, Huayan ; Sun, Yingjia..
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586749/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
8

Advances in immunotherapy of advanced non-small cell lung c..:

HUANG Huayan ; XU-ZHANG Wendi ; XIA Liliang..
https://xuebao.shsmu.edu.cn/article/2023/1674-8115/1674-8115-2023-43-5-611.shtml.  , 2023
Link: https://doi.org/10.3969/..
 
?
9

Comprehensive analysis of MET mutations in NSCLC patients i..:

Ai, Xinghao ; Yu, Yongfeng ; Zhao, Jun...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290171/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
10

Comparison of Efficacy and Safety of Brigatinib in First-Li..:

Yu, Yongfeng ; Zhu, Fanfan ; Zhang, Wenxin.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181407/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
11

Homologous recombination deficiency (HRD) can predict the t..:

Zhou, Zhen ; Ding, Zhengping ; Yuan, Jie...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118717/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
12

SMO mutation predicts the effect of immune checkpoint inhib..:

Ji, Wenxiang ; Niu, Xiaomin ; Yu, Yongfeng...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669061/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
13

Circulating tumour DNA biomarkers in savolitinib-treated pa..:

Yu, Yongfeng ; Ren, Yongxin ; Fang, Jian...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629582/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
14

Distinct profile of cell-free DNA in malignant pleural effu..:

Yu, Yongfeng ; Qian, Jie ; Shen, Lan..
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893565/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
15

Modelled Economic Analysis for Dacomitinib–A Cost Effective..:

Yu, Yong-feng ; Luan, Luan ; Zhu, Fan-fan...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712321/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
1-15